Real-World Evidence Associated With a First-Generation BTK Inhibitor in Patients With CLL/SLL

This publication is sponsored by BeiGene, USA.

The results of a claims-based analysis presented at AMCP Nexus 2021 revealed that patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who developed atrial fibrillation within the first 12 months of starting treatment with a first-generation Bruton tyrosine kinase inhibitor discontinued therapy at a greater rate, utilized health care resources at a greater rate, and incurred higher average nontreatment-related health care costs during that period than did similar patients who did not develop AF.

This Product Theater Recap includes highlights from the presentation as well as insights from principal investigator, Kathryn Fitch, RN, MEd, who discusses the study’s findings regarding treatment patterns among patients who developed new AF after starting ibrutinib, the costs associated with the development of new AF, and her team’s recent research in this field. In a final interview, Michael Kolodziej, MD, FACP, medical oncologist and Senior Advisor at ADVI Health, LLC, considers the analysis and its potential implications for managed care.